VanEck Pharmaceutical ETF (PPH)
| Assets | $694.00M |
| Expense Ratio | 0.36% |
| PE Ratio | 22.62 |
| Shares Out | 7.34M |
| Dividend (ttm) | $1.61 |
| Dividend Yield | 1.71% |
| Ex-Dividend Date | Oct 1, 2024 |
| Payout Ratio | 39.20% |
| 1-Year Return | +20.32% |
| Volume | 48,284 |
| Open | 94.49 |
| Previous Close | 94.67 |
| Day's Range | 93.59 - 94.69 |
| 52-Week Low | 74.05 |
| 52-Week High | 99.51 |
| Beta | 0.64 |
| Holdings | 27 |
| Inception Date | Feb 1, 2000 |
About PPH
Fund Home PageThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.
Top 10 Holdings
63.82% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 13.35% |
| Novo Nordisk A/S | NVO | 8.31% |
| Johnson & Johnson | JNJ | 6.69% |
| AbbVie Inc. | ABBV | 5.98% |
| Novartis AG | NVS | 5.20% |
| Bristol-Myers Squibb Company | BMY | 5.05% |
| AstraZeneca PLC | AZN | 4.98% |
| Merck & Co., Inc. | MRK | 4.94% |
| Zoetis Inc. | ZTS | 4.69% |
| Cencora, Inc. | COR | 4.63% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Oct 1, 2024 | $0.409 | Oct 4, 2024 |
| Jul 1, 2024 | $0.3558 | Jul 5, 2024 |
| Apr 1, 2024 | $0.5328 | Apr 5, 2024 |
| Dec 27, 2023 | $0.3074 | Dec 29, 2023 |
| Oct 2, 2023 | $0.3398 | Oct 6, 2023 |
| Jul 3, 2023 | $0.3891 | Jul 7, 2023 |
News
Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH
The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high p...
Healthcare ETFs Starting to Look Healthy
The healthcare sector hasn't been a bad performer, per se. Year-to-date, the S&P Health Care Select Sector Index is up 13.1%, but that lags the S&P 500 by 800 basis points, confirming investors have c...
This Pharma ETF Could Be Ideal Healthcare Pick
Broadly speaking, the healthcare sector remains a laggard relative to the broader market. As of Aug. 28, the S&P Select Sector Health Care Index was trailing the S&P 500 by 310 basis points on a year-...
PPH: A Strong Fund To Play Big Pharma
The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat ...
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a ...
PPH: Ignore The Election Scare, Buy Pharma And Healthcare
Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms...
Healthcare In 2024: Navigating The Biopharma Bull Run
The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to...
Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.
Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.
Biotech Stocks Are Rallying, but the Outlook Isn't Good
The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.
PPH: A 'Shot In The Arm' For Investors Looking To Capitalize On Recent Pharmaceutical Advances
VanEck Pharmaceutical ETF has had the strongest one-year performance of four major pharmaceutical ETF competitors due to its unique mix of Novo Nordisk, Eli Lilly, and Johnson & Johnson. Eli Lilly, PP...
PPH: GLP-1 Companies And Large-Cap Value Pharma Make For A Compelling Portfolio
Eli Lilly is a mega-cap stock in the Health Care sector that has performed well in 2023, and it's the top holding in the VanEck Pharmaceutical ETF. I have a buy rating on the low-cost and style & geog...
PPH: Unnecessary Volatility In A Relatively Stable Healthcare Sector (Technical Analysis)
Pharmaceutical ETFs like PPH may introduce another layer of risk that could be avoided if one took a broader approach to healthcare investing. Technical Analysis displays that beneath the most recent ...
How The Pharmaceutical Industry Is Using AI
Industry-leading pharmaceutical firms are adopting artificial intelligence to drive value for the future of their enterprise. Several companies in the VanEck Pharmaceutical ETF are currently integrati...
PPH Fell As Much As The Market Despite Resilience
The US market is highly speculative right now, as it's bid up to levels comparable to before stresses in the banking system had been revealed by SVB Financial. PPH, which follows a broad basket of the...
Betting On Biotech
Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow. Passive investors seeking a defensive position might just pu...
PPH Might Be Too Safe For A Recovering Market
We think that the bear market is coming to an end, as it must. The way to go is to invest in higher beta, or at least in more beaten down issues.
PPH Investors Should Keep On Top Of Regulatory Developments
PPH investors own the whole world of bigger to big pharma, where wallet share is primarily in the U.S. Things are changing, however, with Medicare now able to negotiate prices with companies on the mo...
What The Inflation Reduction Act Means For Drug Prices
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...
PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return
Historically, PPH generated a steady total return with a low yield up to 2 percent. PPH's price multiples are considerably lower than its peers and index despite strong earnings and stable historical ...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...